New hope for rare leukemia: drug combo aims for remission and transplant
NCT ID NCT07573670
First seen May 14, 2026 · Last updated May 19, 2026 · Updated 1 time
Summary
This study tests a combination of two drugs (Bcl-2 inhibitor and azacitidine) in people newly diagnosed with a rare, aggressive leukemia called mixed phenotype acute leukemia (MPAL). The goal is to see if this treatment can put the cancer into remission and allow patients to receive a stem cell transplant, which may offer long-term control. The study will enroll 52 participants aged 16 to 70 and follow them for at least 2 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED MIXED PHENOTYPE ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
Conditions
Explore the condition pages connected to this study.